GE Healthcare Announces U.S. FDA 510k Clearance for its Ultra Edition Package on Vivid Cardiovascular Ultrasound Systems

GE Healthcare | October 12, 2020

GE Healthcare today announced U.S. FDA 510k clearance for its Ultra Edition package on Vivid1 cardiovascular ultrasound systems, which includes new features based on artificial intelligence (AI) that enable clinicians to acquire faster, more repeatable exams consistently. Methodical assessments of heart function are key in echocardiography but can be tedious and time-consuming to acquire. High quality data acquisition and operator skill are key elements to achieve accurate and complete exams. And, as patients undergo subsequent monitoring exams, the reproducibility of exam assessments is key to identifying improvement or disease progression. Vivid Ultra Edition brings increased efficiencies to the scanning process for reduced exam time through up to 80% fewer clicks3, 99% accuracy4 and less inter-operator variability.

Spotlight

Your behaviors during the day, and especially before bedtime, can have a major impact on your sleep. They can promote healthy sleep or contribute to sleeplessness. Your daily routines what you eat and drink, the medications you take, how you schedule your days and how you choose to spend your evenings can significantly impact your quality of sleep. Even a few slight adjustments can, in some cases, mean the difference between sound sleep and a restless night. Completing a two-week sleep diarycan help you understand how your routines affect your sleep.

Spotlight

Your behaviors during the day, and especially before bedtime, can have a major impact on your sleep. They can promote healthy sleep or contribute to sleeplessness. Your daily routines what you eat and drink, the medications you take, how you schedule your days and how you choose to spend your evenings can significantly impact your quality of sleep. Even a few slight adjustments can, in some cases, mean the difference between sound sleep and a restless night. Completing a two-week sleep diarycan help you understand how your routines affect your sleep.

Related News

HEALTH TECHNOLOGY

Kepro Completes Acquisition of eQHealth

Kepro | October 01, 2021

Kepro announced today that it has completed the acquisition of eQHealth Solutions, LLC. This acquisition will expand Kepro's population health management and technology solution portfolios. "Today we welcome eQHealth Solutions to the Kepro family. The combination of our companies will support our continued growth and bring further expertise, depth, and tech-enabled solutions to our clients to better serve priority populations." Dr. Susan Weaver, President and Chief Executive Officer, Kepro eQHealth Solutions has been improving healthcare quality and reducing costs through innovative technology, population health management solutions and medical management services since its inception. The company's expansive offerings include eQSuite®, a cloud-based, SaaS technology coupled with eQCare®, a community-based services solution. Synergy Advisors, LLC served as financial advisor to Kepro. Coker Capital, a division of Fifth Third Securities, served as financial advisor to eQHealth Solutions. Jones Walker LLP and Lyle Johnson LLC provided legal services to eQHealth Solutions and Smith, Gambrell & Russell, LLP provided legal services to Kepro. About Kepro Over the past 35 years, Kepro has partnered with government-sponsored and commercial health payers across the country to improve healthcare quality, maximize efficiency and achieve better healthcare outcomes. Kepro provides technology-enabled services for priority populations to help them remain in the home or community of their choice. Today, Kepro serves more than 300 clients including federal, state, and local governments. With 20 offices and over 1,400 employees across the United States, Kepro has improved the lives of more than 77 million beneficiaries nationwide.

Read More

HEALTH TECHNOLOGY

Charles River Launches First Annual Healthcare Collaboration Report

Charles River Laboratories | September 20, 2021

Charles River Laboratories International, Inc.today released the results from its first annual Healthcare Collaboration Report, which identified Americans’ perceptions of healthcare’s strengths and weaknesses, general knowledge of drug and vaccine development, as well as respondents’ key future priorities. The survey, conducted in May of 2021 with The Harris Poll, polled more than 1,500 Americans and found respondents want to see industry players working together, with 64% saying the quality of healthcare would improve with more collaboration. “Working from early-stage research all the way to drug manufacturing, Charles River is in a unique position to understand and appreciate the importance of collaboration across the healthcare industry,” said Jim Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories. “The scientific community’s response to the COVID-19 pandemic demonstrated just how powerful it is when stakeholders across healthcare work closely together. We developed, approved, manufactured, and distributed vaccines at record speed. This report is an important lens into the public’s perception of the industry and why a commitment to maintaining this collaborative effort will be so critical for a strong healthcare system in the future.” Healthcare is broken, collaboration is key to remedy The survey identified that one in three Americans (34%) believe the cost of healthcare is the biggest problem facing the system, followed by the high cost of prescription drugs (18%). Still, it is believed that collaboration has the potential to transform the industry, with 90% of Americans agreeing it will take a united effort of all key players to improve the healthcare system. Other key findings on the potential impact of collaboration across the healthcare industry include: 52% say that closer collaboration would increase the amount of healthcare innovation. Most (84%) also agree greater collaboration across all groups involved in healthcare would help new drug development move more quickly. The government is most likely to be assigned with the responsibility for improving the state of U.S. healthcare (39%), but the government is also the group least likely to be trusted to do what’s best for Americans – less than half (46%) trust the government somewhat or completely to do so. Americans’ industry knowledge presents opportunity for education While half (50%) of Americans think they are knowledgeable about the drug development process, there are clear opportunities for education about the industry. When asked about the amount of time it takes for a potential drug to be developed and approved for market in the U.S., only 10% correctly estimated that it takes between 10 and 15 years. Additional findings regarding Americans’ knowledge of the healthcare industry include: When asked to estimate the percentage of potential new drugs that are approved and make it to market in the United States, the average percentage reported was 36.4%. The actual percentage is closer to .02%. While most know all new vaccines and drugs will not be approved as quickly as the coronavirus vaccines, there are still a fair number of adults who are not sure (60% correctly answered false, 24% not sure). Most say collaboration between groups in the healthcare system was a reason the coronavirus vaccines were able to be approved so quickly (61% correctly answered true, 25% not sure). Pandemic prevention, lowering drug prices critical in the road ahead The pandemic brought the need for future investment and collaboration in vaccine development to the forefront for Americans, with 88% of respondents agreeing that pandemic prevention requires a collaborative effort between government, health insurance companies, pharmaceutical companies, healthcare providers, and patients. Adults are somewhat split on their views about how well they felt the U.S. handled the coronavirus pandemic compared to other countries; however, the majority of Americans – across all political parties – support the increase of taxes for the benefit of healthcare improvements. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com. About the Survey The custom survey was conducted online within the United States by The Harris Poll on behalf of Charles River Labs between May 11 and 24, 2021 among 1,508 adults ages age 18+ living in the United States. All respondents were weighted to align with figures from the US Census Bureau’s March 2020 CPS (Current Population Survey) on education, age by gender, race/ethnicity, region, household income, household size, and marital status for US adults age 18+. Propensity score weighting was also used to adjust for respondents’ propensity to be online

Read More

HEALTH TECHNOLOGY

maiData and inContext.ai Ink a Memorandum of Understanding How Two Healthcare AI Companies Plan to Work

maiData | November 12, 2020

maiData Corporation and inContext.ai today declared fulfillment of a Memorandum of Understanding (MOU) that traces how the two medical services AI organizations intend to cooperate to quicken AI development and arrangement. Under the details of the MOU, maiData will coordinate Natural Language Processing (NLP) innovation from inContext.ai into its maiVA programming, which maiData with then use to recognize semantically applicable subsets of clinical information for pseudonymization, extraction and conveyance to clients. The expansion of NLP innovation from inContext.ai into maiVA programming will permit maiData clients to indicate more refined inquiry and surmising standards, and will give more nuanced, interoperable details about the clinical information that is gathered. “The integration of the inContext.ai technology into our platform will allow us to rapidly locate the data desired by our customers from within medical reports. It will increase the precision with which we can locate the exact data that our customers require,” said Julian Marshall, CEO of maiData. “This will be the most streamlined approach to medical data collection that our customers have ever known.” Robert Grzeszczuk, CEO of inContext.ai, said “Our company is excited to have been selected by maiData to provide our Natural Language Processing technology. Our deep experience in general language understanding will help maiData deliver targeted clinical information to the AI developers, Contract Research Organizations (CROs) and Pharmaceutical companies that they serve.” maiData has built up a smoothed out way to deal with information assortment that will extraordinarily decrease the difficulties related with customary strategies for curating information for the turn of events and testing of clinical AI calculations. Filling in as the extension between clinical information sources and clinical AI designers, maiData quickens AI advancement and organization. inContext.ai creates intellectual innovation and apparatuses that smooth out conveyance of patient consideration and reduction clinical blunders by helping clinicians center around what they excel at: thinking about patients. Execution of inContext.ai's Deep Artificial Intelligence (AI) apparatuses supporting Natural Language Processing (NLP) undertakings including Question Answering (QA), Reading Comprehension (RC), and Natural Language Inference (NLI), which consistently synchronize with EHR frameworks, implies medical services suppliers remain in consistence with clinical/lawful/administrative obligations, fundamentally improve cost, quality, and admittance to mind. About maiData Corporation: maiData Corporation is a new Silicon Valley startup company. maiData fulfills its mission of “Bringing A.I. to Life” by focusing on helping developers improve the quality and generalizability of their algorithms and helping CROs expand the scale of the clinical studies they can perform. About inContext.ai: inContext.ai is a premier natural language processing AI company based in Houston whose technologies help medical providers and companies leverage the rich data in medical reports in new ways. InContext.ai’s research is funded in part by a generous National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant.

Read More